Amarin Corp Plcuk (AMRN) Amortizatization of Intangibles (2012 - 2026)
Amarin Corp Plcuk (AMRN) reported Amortizatization of Intangibles of $637000.0 for Q1 2026, down 47.62% year-over-year from $1.2 million in Q1 2025, and down 9.13% quarter-over-quarter from $701000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 15 years of Amortizatization of Intangibles data on file, last reported at $637000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $637000.0, down 47.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 27.81% YoY), and the FY2025 annual result was $3.0 million, up 4.28% from the prior year.
- Amortizatization of Intangibles retreated to $637000.0 in Q1 2026 per AMRN's latest filing, from $701000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.0 million in Q2 2024 and troughed at -$2.4 million in Q4 2022.
- A 5-year average of $523117.6 and a median of $701000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles soared 342.51% in 2023, then plunged 280.17% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at -$2.4 million in 2022, then surged by 129.43% to $701000.0 in 2023, then sank by 280.17% to -$1.3 million in 2024, then surged by 155.5% to $701000.0 in 2025, then dropped by 9.13% to $637000.0 in 2026.
- Business Quant data shows AMRN's Amortizatization of Intangibles at $637000.0 in Q1 2026, $701000.0 in Q4 2025, and $134000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 637,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 637,000.00 |
| Mar 31, 2026 | 637,000.00 |
| Dec 31, 2025 | 701,000.00 |
| Dec 31, 2025 | 701,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 973,000.00 |
| Jun 30, 2025 | 973,000.00 |
| Mar 31, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 729,000.00 |
| Mar 31, 2024 | 729,000.00 |
| Dec 31, 2023 | 701,000.00 |
| Dec 31, 2023 | 701,000.00 |